Core Insights - CytomX is an oncology-focused biologics company that has developed a unique Probody therapeutic platform aimed at improving the therapeutic window for potent anticancer agents [1] - The company has pioneered the concept of antibody masking, which has been in development for approximately 15 years [1] - CytomX is currently advancing two clinical programs: CX-2051, an EpCAM-targeted masked antibody-drug conjugate, and CX-801, a masked version of interferon alpha-2b [1]

Core Insights - CytomX is an oncology-focused biologics company that has developed a unique Probody therapeutic platform aimed at improving the therapeutic window for potent anticancer agents [1] - The company has pioneered the concept of antibody masking, which has been in development for approximately 15 years [1] - CytomX is currently advancing two clinical programs: CX-2051, an EpCAM-targeted masked antibody-drug conjugate, and CX-801, a masked version of interferon alpha-2b [1]